NCT02135640COMPLETEDanonymous

A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

denosumab 60mg, denosumab 120 mg, placebo

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

denosumab 60mg, denosumab 120 mg, placebo

Related intelligence directories

Indication directory: Osteoporosis Modality directory: monoclonal antibody Target directory: denosumab 60mg

Source & freshness

Source record

NCT ID

NCT02135640

Original source

ClinicalTrials.gov

Source last updated

May 10, 2017

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02135640

Title

A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

PHASE1

Condition raw

Osteoporosis

Condition normalized

Osteoporosis

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

denosumab 60mg, denosumab 120 mg, placebo

Target normalized

denosumab 60mg, denosumab 120 mg, placebo

Interventions

denosumab 60mg, denosumab 120 mg, placebo

Public preview

Source record

This study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of denosumab administered subcutaneously to healthy adults in China.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT02135640

Status

COMPLETED

Phase

PHASE1

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

This study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of denosumab administered subcutaneously to healthy adults in China.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 10, 2017

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02135640

Indication

Osteoporosis

Modality

monoclonal antibody

Target

denosumab 60mg, denosumab 120 mg, placebo

Intervention

denosumab 60mg, denosumab 120 mg, placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.